Regulators assess risk-benefit profile of hypertension drug aliskiren

12/22/2011 | Wall Street Journal, The · Toronto Star, The

European and Canadian regulators are evaluating widely prescribed anti-hypertensive aliskiren amid concerns about its safety. Maker Novartis recently halted a major clinical study on aliskiren's wider use because of high adverse reactions among users with type 2 diabetes and renal impairment, and the drug proved less effective than placebo. Aliskiren is named Tekturna in the U.S. and Rasilez in the EU.

View Full Article in:

Wall Street Journal, The · Toronto Star, The

Published in Briefs: